New drug combo shows promise for Tough-to-Treat breast cancer
Disease control
Recruiting now
This study tracks about 300 women with HER2-positive breast cancer that has spread. They receive a three-drug combination (tucatinib, capecitabine, trastuzumab) as part of their normal care. The goal is to see how well the treatment works and how safe it is in everyday medical pr…
Sponsor: Fondazione Oncotech • Aim: Disease control
Last updated May 16, 2026 23:33 UTC